Frode Selheim

Frode Selheim is a Professor at the Department of Biomedicine, Faculty of Medicine, University of Bergen, where he conducts research in proteomics, systems biology, and translational cell signaling, with a focus on acute myeloid leukemia (AML). He is affiliated with the PROBE research group, specializing in Proteomics and Bioinformatics.

• University: University of Bergen
• School: Faculty of Medicine
• Department: Department of Biomedicine
• Research Groups: PROBE, Systems Biology and Translational Cell Signaling, Research Group for Proteomics and Bioinformatics

Research Interests: His primary research areas include proteomics, phosphoproteomics, signal transduction, cancer biology, and biomarker discovery in AML. He investigates mitochondrial metabolism, post-translational modifications, and cell signaling pathways such as PI3K-Akt-mTOR and cAMP. His work emphasizes patient heterogeneity, therapeutic resistance, and translational applications using mass spectrometry-based workflows.

Publication Trends: His recent publications (2019–2025) show a strong focus on AML, particularly monocytic differentiation, relapse prediction, mitochondrial protein expression, and targeted therapies. The research integrates proteomic and phosphoproteomic profiling to understand disease mechanisms and identify biomarkers. There is a clear trend toward clinical translation, patient stratification, and therapeutic targeting based on molecular signatures.

Scientific Awards:

• No specific awards mentioned in the text.

Advising and Grants: He has supervised numerous master’s and doctoral students, including Rebecca Wangen, Elise Aasebø, and Frode Berven. He is involved in significant research projects related to proteomics and cancer biology, likely supported by national and institutional grants, though specific funding bodies are not listed. His leadership in the PROBE platform indicates active grant involvement in proteomics infrastructure.

Labs and Teams: He is a key member of the PROBE (Proteomics and Bioinformatics) research group at the University of Bergen, which serves as a national platform for proteomics. His team collaborates extensively on AML research, focusing on sample preparation workflows, data interpretation, and translational applications. The group utilizes advanced mass spectrometry and bioinformatics tools to analyze patient-derived samples.